



**Department of Defense
US Army Medical Research
and Materiel Command**



**Fiscal Year 2004 (FY04)
Ovarian Cancer Research Program (OCRCP)
Funded Awards List**

TABLE OF CONTENTS

Introduction

Research Awards

- ◆ HBCU/MI* New Investigator Research
- ◆ Idea Development
- ◆ New Investigator

Participants

- ◆ Peer Reviewers
- ◆ Integration Panel Members

Glossary of Terms

*Historically Black Colleges and Universities/Minority Institutions

Introduction

The US Army Medical Research and Materiel Command (USAMRMC) is pleased to present the awards list of funded projects for the fiscal year 2004 (FY04) Ovarian Cancer Research Program (OCRP). Award negotiations were completed in November 2004. The awards listed in this document were selected in a competitive, two-tier review process. Funding decisions were based on evaluations of scientific excellence in the first tier, followed by determinations of programmatic relevance in the second tier. These projects represent a diverse portfolio of scientific research in three program emphasis areas: (1) Etiology/tumor biology, (2) preclinical development of targeted therapeutics (excluding clinical trials), and (3) molecular imaging/vital imaging of ovarian cancer.

Congressional direction for FY04 specified \$10 million for ovarian cancer research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, award recommendations were made, and contract negotiations were completed. A total of 12 awards was made.

The FY04 programmatic strategy called for Idea Development and New Investigator Research Awards. The intent of the Idea Development Award is to encourage innovative approaches to ovarian cancer research, and the New Investigator Research Award is intended to support the career transition and/or development of independent researchers in ovarian cancer research.

As the funded investigators embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific, clinical, and consumer advisors. The expertise, vision, and diversity of perspective of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons affected by ovarian cancer. It is with great anticipation and excitement that we await the outcomes of this body of research.

*Historically Black Colleges and Universities/Minority Institutions
New Investigator Research Award*

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
OC040121	Aikhionbare	Felix	Morehouse School of Medicine	Mitochondrial DNA Mutations in Epithelial Ovarian Tumor Progression	\$300,000

Idea Development Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
OC040010	Curiel	David	University of Alabama at Birmingham	A Double Selection Approach to Achieve Specific Expression of Toxin Genes for Ovarian Cancer Gene Therapy	\$559,890
OC040017	Murphy	Susan	Duke University Medical Center	Epigenetic Characterization of Ovarian Cancer	\$699,996
OC040055	Jacks	Tyler	Massachusetts Institute of Technology	Role of Endometriosis in the Pathogenesis of Ovarian Cancer	\$770,669
OC040066	Kopecek	Jindrich	University of Utah	Double-Targeted Macromolecular Therapeutics for the Treatment of Ovarian Cancer	\$897,000
OC040110	Batra	Surinder	University of Nebraska	Mucins in Human Ovarian Carcinomas	\$600,024
OC040161	Mathis	James	Louisiana State University Health Sciences Center	Dendritic Cell-Based Genetic Immunotherapy for Ovarian Cancer	\$740,042
OC040222	Cheng	Jin	University of South Florida	Aurora-A Oncogene in Human Ovarian Cancer	\$845,926

New Investigator Award

Log Number	PI Last Name	PI First Name	PI Institution	Proposal Title	Final Budget
OC040038	Jurisica	Igor	University of Toronto, University Health Network, PMH/OCI	Integrated Computational Biology Approach to Marker Selection for Early Detection and Treatment of Epithelial Ovarian Cancer	\$640,347
OC040060	Wang	Tian-Li	Johns Hopkins University School of Medicine	Identification and Characterization of Genomic Amplifications in Ovarian Serous Carcinoma	\$979,230
OC040133	Hogan	Kevin	University of Virginia	Identification and Characterization of Ovarian Carcinoma Peptide Epitopes Recognized by Cytotoxic T Lymphocytes	\$914,167
OC040187	Liu	Bin	University of California, San Francisco	Defining and Targeting of an Ovarian Cancer-Specific Internalizing Epitope Space	\$664,067

**Fiscal Year 2004 Ovarian Cancer Research Program
Peer Reviewers**

Peer Reviewers	Degree	Institution/Affiliation
Aldaz, Claudio	M.D., Ph.D.	University of Texas MD Anderson Cancer Center
Bast, Robert	M.D.	University of Texas MD Anderson Cancer Center
Beck, William	Ph.D.	University of Illinois at Chicago
Benbrook, Doris	Ph.D.	University of Oklahoma Health Sciences Center
Berek, Jonathan	M.D.	University of California, Los Angeles School of Medicine
Blasberg, Ronald	M.D.	Memorial Sloan-Kettering Cancer Center
Bonavida, Benjamin	Ph.D.	University of California Los Angeles School of Medicine
Bremner, Theodore	Ph.D.	Howard University
Brewer, Molly	D.V.M., M.D.	University of Arizona
Britten, Richard	Ph.D.	Eastern Virginia Medical School
Buller, Richard	M.D., Ph.D.	GlaxoSmithKline
Cannon, Martin	Ph.D.	University of Arkansas for Medical Sciences
Carter, JoAnn		Ovarian Cancer National Alliance
Chambers, Setsuko	M.D.	Yale University
Ciesla, Maria		National Ovarian Cancer Coalition
Coats, Steven	Ph.D.	Amgen, Inc.
Cohen, Marion	Ph.D.	University of Medicine & Dentistry of New Jersey
Daoud, Sayed	Ph.D.	Washington State University
Deuel, Thomas	M.D.	The Scripps Research Institute
Eckhart, Walter	Ph.D.	The Salk Institute
Elit, Laurie	M.D.	Hamilton Regional Cancer Centre
Feder, Davida		Ovarian Cancer National Alliance
Godwin, Andrew	Ph.D.	Fox Chase Cancer Center
Groden, Joanna	Ph.D.	University of Cincinnati
Haber, Roberta	Ph.D.	Scientific Review Administrator
Hickey, Robert	Ph.D.	Indiana University School of Medicine
Horowitz, Jonathan	Ph.D.	North Carolina State University College of Veterinary Medicine
Johnson, Steven	Ph.D.	University of Pennsylvania

Peer Reviewers	Degree	Institution/Affiliation
Kalli, Kimberly	Ph.D.	Mayo Clinic College of Medicine
Kane, Madeleine	M.D., Ph.D.	University of Colorado Health Science Center
Knutson, Keith	Ph.D.	University of Washington Tumor Vaccine Group
Kruk, Patricia	Ph.D.	University of South Florida
Link, Charles	M.D.	Iowa Cancer Research Foundation
Magnan, Mary		Ovarian Cancer Education Awareness Network (OCEAN)
Malkas, Linda	Ph.D.	Indiana University School of Medicine
Mayer, Bruce	Ph.D.	University of Connecticut Health Center
McGuffie, Eileen	Ph.D.	Scientific Review Administrator
Modugno, Francesmary	Ph.D., M.P.H.	University of Pittsburgh
Molina, Carlos	Ph.D.	UMDNJ-New Jersey Medical School
Morin, Patrice	Ph.D.	National Institute on Aging, National Institutes of Health
Muller, Carolyn	M.D.	University of Texas Southwestern Medical Center
Naschinski, Charlotte		Ovarian & Gynecological Cancer Coalition of Greater Washington
Nephew, Kenneth	Ph.D.	Indiana University School of Medicine
Ochieng, Josiah	Ph.D.	Meharry Medical College
Palmer, Winifred	Ph.D.	Scientific Review Administrator
Patriotis, Christos	Ph.D.	Fox Chase Cancer Center
Penn, Linda	Ph.D.	Ontario Cancer Institute
Pieretti, Maura	Ph.D.	BayCare Laboratories
Platsoucas, Chris	Ph.D.	Temple University School of Medicine
Potter, Philip	Ph.D.	St. Jude Children's Research Hospital
Richard, Nyrvah		SHARE: Self Help for Women w/Breast or Ovarian Cancer
Rosen, Eliot	M.D., Ph.D.	Georgetown University/Lombardi Comprehensive Cancer Center
Schilder, Russell	M.D.	Fox Chase Cancer Center
Schmitt, Mark	Ph.D.	SUNY Upstate Medical University
Shabb, John	Ph.D.	University of North Dakota School of Medicine
Siegal, Gene	M.D., Ph.D.	University of Alabama at Birmingham
Skubitz, Amy	PhD	University of Minnesota

Peer Reviewers	Degree	Institution/Affiliation
Stack, Mary	Ph.D.	Northwestern University
Stone, Robin		Gilda's Club Metro Detroit
Taylor, Christopher	Ph.D.	Lombardi Cancer Center, Georgetown University Medical Center
Tonin, Patricia	Ph.D.	McGill University
Tung, Ching	Ph.D.	Massachusetts General Hospital
VanDewark, Marcia		National Ovarian Cancer Coalition
Wilson, LaTrisha		SHARE
Worsham, Maria	Ph.D.	Henry Ford Health System
Xu, Yan	Ph.D.	Cleveland Clinic Foundation
Zou, Weiping	M.D., Ph.D.	Tulane University Medical School

**Fiscal Year 2004 Ovarian Cancer Research Program
Integration Panel Members**

IP Members	Degree	Institution/Affiliation
Alvarez, Ronald (Chair)	M.D.	University of Alabama at Birmingham
Basilion, James	Ph.D.	Massachusetts General Hospital
Bell, Debra	M.D.	Massachusetts General Hospital
Boyd, Jeffrey	Ph.D.	Memorial Sloan-Kettering Cancer Center
Cho, Kathleen	M.D.	University of Michigan Medical School
Gershenson, David (Chair Emeritus)	M.D.	University of Texas MD Anderson Cancer Center
Goldman, Patricia		Ovarian Cancer National Alliance
Hamilton, Thomas	Ph.D.	Fox Chase Cancer Center
Kohn, Elise	M.D.	National Cancer Institute
Maihle, Nita	Ph.D.	Yale University School of Medicine
Markman, Maurie	M.D.	University of Texas MD Anderson Cancer Center
Robinson, Elwood	Ph.D.	North Carolina Central University
Rubin, Stephen (Chair Elect)	M.D.	The University of Pennsylvania Medical Center
Scroggins, Mary (Executive Committee Member-at-Large)	M.A.	Ovarian Cancer National Alliance

Glossary of Terms

Idea Development Award: The intent of this award mechanism is to encourage innovative approaches to ovarian cancer research. Idea Development Awards were required to address at least one of the program emphasis areas (i.e., etiology/tumor biology, preclinical development of targeted therapies [excluding clinical trials], or molecular imaging/vital imaging of ovarian cancer). Investigators from all academic levels were eligible to submit proposals; however, preliminary data relevant to ovarian cancer research and the proposed project were required.

New Investigator Research Award: The intent of the New Investigator Research Award is to recognize and support the career transition and/or development of independent researchers in ovarian cancer research. This mechanism was open to independent, established scientists or clinicians with fewer than three years of experience in ovarian cancer research and independent investigators at the junior faculty level within five years of their last fellowship, postdoctoral, or other training position. New Investigator Research Awards were required to address etiology/tumor biology, preclinical development of targeted therapeutics (excluding clinical trials), or molecular imaging/vital imaging of ovarian cancer. Applicants were required to provide preliminary data relevant to the proposed project but not necessarily in ovarian cancer.